Canagliflozin had beneficial effects on body weight, BMI, waist circumference, SBP, DBP and HDL-C compared with glimepiride or sitagliptin in T2DM patients with metabolic syndrome.
Based on EMPA-REG OUTCOME data, the European Commission has for the first time approved an agent against type 2 diabetes, empagliflozin, to both lower blood glucose and the risk of CV events.
Dr. Jorge Plutzky, MD, discusses the ability to modulate and modify CV risk with new antidiabetic agents. The use of an SGLT2 inhibitor or a GLP1 agonist should be considered in appropriate patients with diabetes.
The SGLT2 inhibitor empagliflozin is the first type 2 diabetes treatment that receives this additional indication based on the CV survival benefit seen the EMPA-REG OUTCOME trial.
CSI Rome Manon Slob and Shahnam Sharif extensively discuss the results of the EMPA-REG OUTCOME study, the first outcomes trial with an SGLT2 inhibitor, with Prof. Silvio Inzucchi, including what the results may mean for the management of diabetes.
The SGLT2 inhibitor ertugliflozin, when given in addition to background therapy of sitagliptin and stable metformin therapy, showed greater reductions in HbA1C in patients with T2DM, as compared with placebo, in the VERTIS SITA2 study.
PERSPECTIVE A 5% significance level more than ‘just’ a positive outcome. There are multiple aspects that need to be considered to classsify a clinical trial as positive.
During a satellite symposium at the ESC 2016 in Rome, organised by PACE-CME, the impact of CV disease in patients with diabetes, SGLT-2 inhibitor trial outcome data as well as the mechanism by which SGLT-2 inhibitors may affect heart function, were discussed
Since 1995, every 3-4 years a new anti-hyperglycemic category of medication has been introduced, including the SGLT-2 inhibitors in 2013
Until very recently, heart failure as a problem in diabetes was largely ignored, although it is one of the most common and most important complications in diabetes. But the EMPA-REG OUTCOME study6 put heart failure on the map; SGLT-2 inhibitors showed a remarkable reduction in heart failure hospitalisation and mortality.
Good glycaemic control can now be achieved with a lower risk of hypoglycaemia than before. Prof. Groop elaborates on the evidence on whether improving glycaemic control with DPP-4 inhibitors translates into a reduction of renal complications.
Recent outcome studies have shown evidence for a CV benefit with novel antidiabetic therapies such as DPP4 inhibitors and SGLT2 inhibitors. Dr. Pratley summarises the observations and speculates on how these findings may affect treatment of patients with diabetes in the near future.